Abstract
Background: ESR1 is expressed by 60–70% of breast tumours. it’s a good prognosis factor and the target of hormone therapy. Optimization of ESR1 reactivation therapy is currently ongoing. Here we probe if the transcription factor CTCF plays a role in the differential expression of ESR1 in the breast cancer cell lines MCF-7 (ESR1+) and MDA-MB-231 (ESR1-). Methods and results: Knockdown of CTCF in MCF-7 resulted in decreased ESR1 gene expression. CTCF binds to the promoter of ESR1 in MCF-7 but not in MDA-MB-231 cells. CTCF ESR1 binding sites are unmethylated in MCF7 but methylated in MDA-MB-231 cells. Conclusion: ESR1 expression in MCF7 cells is dependent on CTCF expression. CTCF can bind to specific regions of the promotor of ESR1 gene in MCF-7 cells but not in MDA-MB-231 cells, this correlates with the methylation status of these regions and could be involved in the transcriptional regulation of ESR1.
Author supplied keywords
Cite
CITATION STYLE
Montes-de-Oca-Fuentes, E. V., Jácome-López, K., Zarco-Mendoza, A., Guerrero, G., Ventura-Gallegos, J. L., Juárez-Méndez, S., … Zentella-Dehesa, A. (2024). Differential DNA methylation and CTCF binding between the ESR1 promoter a of MCF-7 and MDA-MB-231 breast cancer cells. Molecular Biology Reports, 51(1). https://doi.org/10.1007/s11033-023-09171-0
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.